Astellas tests gamification ideas with Japanese universitiesAstellas has teamed up with Tokyo University of the Arts and Yokohama City University to create and commercialise Share XAstellas tests gamification ideas with Japanese universitieshttps://pharmaphorum.com/news/astellas-tests-gamification-ideas-with-japanese-universities/
Astellas pushes non-hormonal menopause drug into phase 3Japan’s Astellas has started treating patients in a phase 3 trial of fezolinetant, a non-hormonal drug for menopausal Share XAstellas pushes non-hormonal menopause drug into phase 3https://pharmaphorum.com/news/astellas-pushes-non-hormonal-menopause-drug-into-phase-3/
Bayer aims at J&J and Pfizer with new prostate cancer drugThe FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease Share XBayer aims at J&J and Pfizer with new prostate cancer drughttps://pharmaphorum.com/news/bayer-aims-at-jj-and-pfizer-with-new-prostate-cancer-drug/
EMA starts review of Xtandi in hormone-sensitive prostate cancerThe EU regulator has started the clock ticking on its review of Pfizer and Astellas’ prostate cancer drug Share XEMA starts review of Xtandi in hormone-sensitive prostate cancerhttps://pharmaphorum.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer/
Seattle Genetics and Astellas file bladder cancer drug in USSeattle Genetics and Astellas have filed their antibody-drug conjugate enfortumab vedotin with the US drug regulator for advanced Share XSeattle Genetics and Astellas file bladder cancer drug in UShttps://pharmaphorum.com/news/seattle-genetics-and-astellas-file-bladder-cancer-drug-in-us/
Why pharma needs honest patient dialogueAstellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the Share XWhy pharma needs honest patient dialoguehttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/astellas-pharma-percival-barretto-ko/
Deep Dive: Oncology and ASCO 2019Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this Share XDeep Dive: Oncology and ASCO 2019https://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019
Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinRoche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – Share XAstellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinhttps://pharmaphorum.com/news/astellas-seattle-genetics-target-advanced-bladder-cancer-with-enfortumab-vedotin/
Bayer files prostate cancer drug darolutamide in JapanBayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the Share XBayer files prostate cancer drug darolutamide in Japanhttps://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-in-japan/
